-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Regulus Therapeutics Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate for Q1 2013.
- Regulus Therapeutics Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2013 was -$10K.
- Regulus Therapeutics Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $0.000.
- Regulus Therapeutics Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
- Regulus Therapeutics Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $0.000, a 100% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)